Fmr LLC Raises Stake in 10x Genomics, Inc. (NASDAQ:TXG)

FMR LLC boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,454,434 shares of the company's stock after acquiring an additional 86,455 shares during the period. FMR LLC owned about 11.11% of 10x Genomics worth $193,206,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in TXG. ARK Investment Management LLC boosted its holdings in shares of 10x Genomics by 11.1% in the 4th quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company's stock valued at $171,517,000 after buying an additional 1,193,712 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in 10x Genomics in the fourth quarter valued at approximately $26,308,000. Geode Capital Management LLC grew its holdings in 10x Genomics by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company's stock worth $41,009,000 after purchasing an additional 42,777 shares during the last quarter. State Street Corp grew its holdings in 10x Genomics by 7.1% in the third quarter. State Street Corp now owns 1,750,643 shares of the company's stock worth $39,530,000 after purchasing an additional 116,534 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of 10x Genomics by 11.7% during the 3rd quarter. Barclays PLC now owns 602,536 shares of the company's stock valued at $13,605,000 after purchasing an additional 63,079 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on TXG shares. Stifel Nicolaus dropped their target price on 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Weiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a research note on Tuesday, April 8th. Morgan Stanley decreased their price objective on shares of 10x Genomics from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Canaccord Genuity Group dropped their target price on shares of 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. decreased their price target on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, 10x Genomics presently has a consensus rating of "Hold" and a consensus price target of $19.79.

Insiders Place Their Bets

In related news, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the transaction, the chief executive officer now owns 879,482 shares in the company, valued at $9,735,865.74. The trade was a 0.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Alan Mateo purchased 40,000 shares of 10x Genomics stock in a transaction that occurred on Friday, February 21st. The stock was acquired at an average cost of $11.14 per share, with a total value of $445,600.00. Following the acquisition, the director now directly owns 61,691 shares in the company, valued at $687,237.74. This trade represents a 184.41 % increase in their position. The disclosure for this purchase can be found here. Insiders own 10.03% of the company's stock.

10x Genomics Stock Performance

10x Genomics stock traded down $0.52 during midday trading on Friday, hitting $7.51. 6,488,585 shares of the company were exchanged, compared to its average volume of 2,197,433. The business has a fifty day simple moving average of $9.96 and a two-hundred day simple moving average of $13.61. The firm has a market capitalization of $918.49 million, a PE ratio of -4.94 and a beta of 2.01. 10x Genomics, Inc. has a fifty-two week low of $6.78 and a fifty-two week high of $29.45.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.